Penumbra (PEN) Cash from Financing Activities (2014 - 2026)

Penumbra's (PEN) quarterly Cash from Financing Activities came in at -$1.9 million in Q1 2026, down 170.42% year-on-year from $2.7 million in Q1 2025, and down 137.71% on a QoQ basis from $5.1 million in Q4 2025.

Penumbra (PEN) Cash from Financing Activities (2014 - 2026) Analysis & Trends

Penumbra (PEN) has 13 years of Cash from Financing Activities data on file, last reported at -$1.9 million in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 170.42% year-over-year to -$1.9 million in Q1 2026; TTM through Mar 2026 was $21.9 million, a 126.25% increase from a year earlier, with the FY2025 full-year figure at $26.5 million, up 130.49% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at -$1.9 million, down from $5.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PEN reached as high as $14.8 million in Q2 2025 and fell as low as -$100.6 million in Q3 2024.
  • Historically, Cash from Financing Activities has averaged -$2.0 million across 5 years, with a median of $4.0 million in 2025.
  • Across the five-year window, Cash from Financing Activities slumped 47531.13% in 2024 and soared 441.06% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at $5.7 million in 2022, then gained by 3.24% to $5.9 million in 2023, then grew by 2.48% to $6.1 million in 2024, then decreased by 16.66% to $5.1 million in 2025, then slumped by 137.71% to -$1.9 million in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.9 million in Q1 2026, $5.1 million in Q4 2025, and $4.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 17.31 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -1.51 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn -888.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -260.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -451.20 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -25.00 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -26.93 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 21.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Penumbra 12.48 Bn 11.87 Bn 253.41 Mn -1.91 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.91 Mn
Mar 31, 2026 -1.91 Mn
Dec 31, 2025 5.06 Mn
Dec 31, 2025 5.06 Mn
Sep 30, 2025 3.95 Mn
Sep 30, 2025 3.95 Mn
Jun 30, 2025 14.82 Mn
Jun 30, 2025 14.82 Mn
Mar 31, 2025 2.71 Mn
Mar 31, 2025 2.71 Mn
Dec 31, 2024 6.07 Mn
Dec 31, 2024 6.07 Mn
Sep 30, 2024 -100.55 Mn
Sep 30, 2024 -100.55 Mn
Jun 30, 2024 8.27 Mn
Jun 30, 2024 8.27 Mn
Mar 31, 2024 -794,000.00
Mar 31, 2024 -794,000.00
Dec 31, 2023 5.92 Mn
Dec 31, 2023 5.92 Mn